Key facts
- This page summarizes Michael S. Klein's Form 4 filing for ICAD INC (ICAD).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 Mar 2023, 20:35.
Michael S. Klein - 16 Nov 2018 Form 4 Insider Report for ICAD INC (ICAD)
- Reporting relationship
- Director
- Issuer ticker
- ICAD
- Reported as of
- 16 Nov 2018
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Mar 2023, 20:35:33 UTC
- Next SEC filing
- 19 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/Michael Klein
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael S. Klein filed Form 4 for ICAD INC (ICAD) on 09 Mar 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ICAD
transaction
Derivative
Director Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -90,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Nov 2018
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 90,000
- Exercise price
- $2.89
- Footnotes
- F1, F2
ICAD
transaction
Derivative
Director Stock Option (right to buy)
Award
- Transaction value
- Shares
- +90,000
- Change %
- Price
- Shares after
- 90,000
- Date
- 07 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 90,000
- Exercise price
- $2.89
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years.? No other modification was made to the option.
Footnote F2
The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 16, 2018 and is fully vested as of the date hereof.